The Galien Foundation recently announced the winners of the 2024 Prix Galien UK Awards, with the University of Oxford receiving accolades for its
groundbreaking contributions to public sector innovation through the PRINCIPLE and PANORAMIC Trials.
These trials, spearheaded by Oxford's team of experts, have set a new standard for scientific innovation aimed at improving global health outcomes.
Led by University of Oxford, the PRINCIPLE and PANORAMIC Trials epitomize a remarkable collaboration aimed at combating the COVID-19 pandemic.
The British scientists behind one of the major therapeutic Covid-19 trials have turned their focus to treatments for monkeypox, a viral disease that has been
labelled a global health emergency by the World Health Organization.
The team from Oxford University behind the so-called RECOVERY trial - which honed in on four effective Covid treatments - on Tuesday unveiled a new trial, dubbed
PLATINUM, to confirm whether Siga Technologies' tecovirimat is an effective treatment for monkeypox.
Although there are vaccines developed for the closely related smallpox that can reduce the risk of catching monkeypox, there are currently no treatments that have
been proven to help hasten recovery in those who develop the disease.
The UK has over 3,000 confirmed cases of monkeypox.
The virus is transmitted chiefly through close contact with an infected person. It typically causes mild symptoms including fever, rash, swollen lymph nodes and
pus-filled skin lesions. Severe cases can occur, though people tend to recover within two to four weeks.
Siga's drug, branded Tpoxx, has been cleared to treat diseases caused by the family of orthopoxvirus that includes smallpox, monkeypox and cowpox by the European
Union and United Kingdom, but due to limited trial data it is generally only used in severe cases in Britain.
Oxford Cannabinoid Technologies Holdings plc, which specialises in developing cannabis-derived medicines with pain-relieving properties, has successfully
administered the first-in-human dose of its lead pharmaceutical drug compound, OCT461201, in its phase 1 clinical trial. The company holds a portfolio of four
drug candidates intended for use as licensed pain medications.
The drug is a selective cannabinoid receptor type 2 agonist with the potential to treat chemotherapy-induced peripheral neuropathy and irritable bowel syndrome.
The UK trial, conducted by Simbec Research Limited, part of Simbec-Orion Group Ltd., is progressing with healthy volunteers, OCTP said in a statement. Using a single
ascending dose protocol, the primary objective is to demonstrate OCT461201's safety and tolerability, while providing information on its pharmacokinetic profile, to
confirm its value as a potential drug.
Results from the trial, funded entirely by OCTP's existing resources, are expected in the third quarter of 2023, the statement added.
Well Pharmacy has acquired three new pharmacies taking the total number of pharmacies owned by the chain across the UK to 746.
The UK's largest independent and third largest pharmacy chain has bought Pharmacy Express in Wakefield, West Yorkshire, and two Frosts Pharmacy's in Banbury, North
Oxfordshire, and Marston, near Oxford. All three pharmacies will be rebranded. #
Well did not disclose the amount it paid for the new acquisitions.
Operations director of Well Pharmacy Louis Purchase said that the group was "excited" to expand. "We believe passionately in community pharmacy, and we want our
offering to be the best experience of this in the UK. We also hope our new colleagues can keep progressing and develop their clinical skills even further by being
part of Well Pharmacy."
Frosts Pharmacy teams have joined Well from their pharmacies based in Ferriston, Banbury, North Oxfordshire and Marston, near Oxford. They both serve local people
from the heart of their communities and offer a successful travel vaccination clinic in Marston.
In a significant move to address health disparities and enhance clinical research, community pharmacies across several regions are set to become central
players in the Genes and Health study.
Led by Queen Mary University of London and funded by the Wellcome Trust, this national initiative aims to improve health outcomes within British-Bangladeshi
and British-Pakistani communities.
Professor Mahendra Patel, Director of the Centre for Research Equity at the University of Oxford, highlighted the importance of this approach.
"By engaging the broader pharmacy workforce, including technicians, we aim to establish a research-ready infrastructure within community pharmacies," Patel
told Pharmacy Business.
He shared that the initiative marks a transformative step in integrating pharmacies into the clinical research landscape.
The Thames Valley and South Midlands Clinical Research Network (CRN) is managing a pioneering pilot program for this study, which will initially focus on
pharmacies in Banbury, Oxford City, Reading, Slough, High Wycombe, and Aylesbury.
In partnership with Oxford University Press, the Royal Pharmaceutical Society (RPS) has launched the 'RPS Pharmacy and Pharmacology' reports.
RPS Pharmacy and Pharmacology Reports is a new, fully open access journal and the sister journal to Journal of Pharmacy & Pharmacology.
The journal is edited by Professor Dennis Douroumis, professor in Pharmaceutical Technology and Process Engineering at the University of Greenwich.
RPS said: "The journal aims to create a truly interdisciplinary forum for members of the pharmacy, pharmacology, chemistry, biochemistry, physiology, and microbiology
communities alike to come together to develop life-changing medicines of the future. The journal prioritises scientifically sound results from pharmacy and
pharmacology researchers across the world."
The journal operates a rapid review and publication process to ensure impactful research is disseminated as quickly as possible.
All RPS members are eligible to receive a 20 per cent discount on the article processing charge.
Community pharmacy is at the heart of one of the most ambitious clinical trials ever undertaken by the UK's primary care network, says senior academic pharmacist
Professor Mahendra Patel.
The PANORAMIC trial has been designed to rapidly evaluate several antiviral treatments over time that could help people at high risk of Covid-19 recover sooner,
prevent the need for hospital admission and so ease the burden on the NHS.
The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC) is a national priority trial led by Oxford University's
Primary Care Clinical Trials Unit.
Lead investigators say the study will enable early and rapid testing of novel antiviral agents and help repurpose existing drugs against Covid-19. As soon as the trial is set up for delivery, it will be open to eligible participants from across the UK.
Prof Patel, a key member of the trial's core team, said: "I'm really excited with this news and also by the prospect that there is a huge potential for pharmacy teams to help play a vital role in supporting this highly ambitious trial, as they have with the PRINCIPLE trial, now the world's largest community based clinical trial for Covid19."
Three leading pharmacists - professor Mahendra Patel, Asif Aziz and Ade Williams - have been recognised in Queen Elizabeth's annual New Year's honours list.
Professor Patel, an academic pharmacist from West Yorkshire, was awarded an OBE for his "services to pharmacy." He told Pharmacy Business: "I am truly honoured and deeply humbled by this highly prestigious award that I have always believed was more deserving for others.
"That's not to say I'm not proud of it - far from it, although for me it's not necessarily about rewards and recognition but more the intricacies of the journey I embark on and the learning and joy that those encounters bring with it.
Most recently, Professor Patel - who has had a broad ranging portfolio career spanning community pharmacy, health education and health promotion, academia, and research - has been involved in promoting clinical trials across community pharmacies in the UK.
His latest work has seen him act as one of the national leads for the PRINCIPLE and PANORAMIC trials, run by Oxford University - both trials seek to pioneer repurposed and new drug treatments in the community to prevent hospitalisation due to Covid-19.
The UK Health Security Agency (UKHSA) and the Office for National Statistics (ONS) will jointly launch a new study to gather data on COVID-19 this winter.
The Winter COVID-19 Infection Study (WCIS) will run from November 2023 to March 2024, involving up to 200,000 participants, UKHSA has said on Monday (October 2).
UKHSA previously commissioned the Coronavirus Infection Survey (CIS), conducted by the ONS in collaboration with scientific study leaders from Oxford University,
analysing more than 11.5 million swab tests and 3 million blood tests from April 2020 to March 2023.
Meanwhile, the Winter CIS study involves conducting up to 32,000 lateral flow tests weekly, providing vital insights into COVID-19 prevalence in the broader
community. The sample will be structured to broadly reflect key population characteristics.
The NHS on Thursday (May 5) said it has rolled out the arthritis drug baricitinib for seriously ill Covid patients.
The Recovery trial, conducted by the NHS and University of Oxford, found that 13 per cent fewer severely ill patients died of Covid when treated with the drug compared to existing treatment options.
Typically used to treat arthritis to reduce pain and inflammation, baricitinib can now be given to hospitalised Covid patients in addition to current treatments, and clinical studies show that this can provide benefits on top of existing treatment.
The NHS has led the rollout of Covid medicines, from the discovery of dexamethasone as the world's first effective treatment, to the first vaccination outside of a clinical trial in December 2020.
The NHS said baricitinib works by reducing inflammation caused by Covid-19 by blocking signals to the immune system that are causing it to attack the body.
Pfizer's oral Covid-19 therapy will be evaluated as a potential treatment for patients hospitalised with the illness in a major British trial, scientists said on Monday, as cases rise in some parts of the world.
The world's largest randomised study of potential medicines for Covid-19, dubbed the RECOVERY trial, will assess Paxlovid across hospitals in Britain, which has already approved the drug for early-stage treatment.
"Paxlovid is a promising oral antiviral drug but we don't know if it can improve survival of patients with severe Covid-19," said Peter Horby, a professor at the University of Oxford and joint chief investigator of the RECOVERY trial.
The scientists said they aim to mainly find whether Pfizer's Paxlovid reduces the risk of death among patients admitted to hospitals with Covid-19.
Professor Mahendra Patel OBE, CEO of the Oxford University Centre for Research Equity (CfRE), has been appointed as an independent expert member of the UK
Pharmacy Professional Leadership Advisory Board.
The newly established Board comprises nine independent expert members (IEMs) with outstanding leadership capabilities, who were appointed through open recruitment,
ensuring a "broad, balanced, and diverse" representation.
Sir Hugh Taylor KCB, the Independent Chair of the Board, and the UK Chief Pharmaceutical Officers (CPhOs) - Andrew Evans (Wales), Cathy Harrison (Northern Ireland),
Alison Strath (Scotland), and David Webb (England) - announced the appointment of IEMs in an open letter to the UK pharmacy professions.
"Bringing a wealth of experience and expertise, they will play a pivotal role in the Board's work to deliver an exciting vision through supporting a new and dynamic
phase of collaboration," the CPhOs said.
As the CEO of CfRE, Professor Patel spearheads efforts aimed at addressing inequalities in healthcare.
In a new study, men who took phosphodiesterase type 5 inhibitors (PDE5Is), such as Viagra (sildenafil; Pfizer), for treatment of erectile dysfunction, were found to be 18 per cent less likely to develop Alzheimer's compared to those who did not take the drugs.
The results of the population-based cohort study were published in Neurology on 7 February 2024.
Researchers at University of Oxford examined IQVIA Medical Research Data UK records of 269,725 men, who were diagnosed with erectile dysfunction between
January 2000 and March 2017.
None of the participants had any memory or thinking problems at the start of the study and they were followed for an average of 5.1 years.
During the study, 749 out of 1,119 participants taking erectile dysfunction drugs developed Alzheimer's disease.
Researchers from the London School of Hygiene & Tropical Medicine (LSHTM) have been tasked to evaluate the impact, safety and effectiveness of the
Pharmacy First service, which was launched across England in January 2024.
They have been awarded £2.4million by the National Institute for Health and Care Research (NIHR) to generate evidence on the new service that allows
pharmacies to provide advice and treatment for seven common conditions without the need for a GP appointment.
After consultation, if necessary, a community pharmacist can supply some prescription-only medicines to treat earache, sore throat, sinusitis, impetigo,
shingles, infected insect bites or uncomplicated urinary tract infections in women.
The LSHTM researcher team will be working together with experts at the UK Health Security Agency (UKHSA) and the Universities of Oxford, Manchester and
Nottingham on the project.
Dr Rebecca Glover, assistant professor in Antimicrobial Resistance at LSHTM, who will lead the three-year project, said they will evaluate "Pharmacy First's
impact on GPs and the wider NHS, pharmacy services and patients."
The NIHR Research Delivery Network (RDN) has published a new paper highlighting the learnings from a major COVID-19 research trial conducted in primary
care settings.
The paper, which draws on insights from the PANORAMIC study, emphasised the importance of prioritising primary care studies from the very start of any pandemic
to prevent worsening of patient symptoms and reduce hospital admission.
Additionally, it recommended considering the use of UK-wide pharmacy networks, including community pharmacies, to promote research inclusion for future similar
trials in primary care to increase recruitment in underserved communities.
Authored by Professor Phil Evans, GP and Deputy Health and Care Director at the NIHR RDN together with colleagues from the NIHR and University of Oxford, the
80-page paper concluded that primary care research should be at the forefront of future pandemic preparedness.
During the early stages of the COVID-19 pandemic, much research was carried out on critically ill patients in secondary care settings.
Boffetta's team found that high consumption of fruit and vegetables gave only a modest protective effect against cancer.
An increase of 200 grammes (about seven ounces) a day resulted in a reduction of cancer risk in the order of some three percent.
The University of Oxford's Centre for Research Equity (CfRE) has entered into a historic partnership with the Health and Social Care Research and
Development (HSC R&D) Division in Northern Ireland to advance health equity across the region and ensure everyone benefits from healthcare advancements.
Unveiled during an event at Parliament Buildings in Stormont Estate on Wednesday, this groundbreaking partnership makes Northern Ireland the first UK region
to partner with CfRE.
Supported by the Department of Health Northern Ireland and key health and social care agencies, the partnership aims to improve health outcomes and reduce
disparities through collaborative research.
Northern Ireland's Health Minister, Mike Nesbitt, highlighted that this new partnership represents "a significant step forward in efforts to address health
inequalities" in the region.
"By bringing together leading experts and resources from across sectors, we can work towards conducting research that truly benefits all of our communities," he
said.